Why Adicet Bio Stock Is Skyrocketing Today
Shares of Adicet Bio (NASDAQ: ACET) were skyrocketing 35.7% as of 11:49 a.m. ET on Monday. This huge gain came after the company announced positive interim data from its phase 1 study evaluating investigational drug ADI-001 in treating B-cell non-Hodgkin's lymphoma.
Were Adicet's phase 1 results really good enough to justify the big move for the biotech stock today? Yep.
Granted, there were only six patients in the study. Two of them weren't able to be evaluated because they didn't reach the day 28 assessment. But three of the four patients who were able to be evaluated achieved responses. Two patients had complete responses, with another patient experiencing what investigators called a "near-complete response."
Source Fool.com
